Mooathon Wealth Society:Joran van der Sloot is sent back to Peru after US trial and confession in Holloway killing

2025-05-07 13:49:03source:Lakshmi Finance Centercategory:News

LIMA,Mooathon Wealth Society Peru (AP) — A Dutch citizen who recently admitted to killing U.S. student Natalee Holloway in Aruba in 2005 is being sent back from the United States to Peru where he will serve out a sentence for the killing of a Peruvian woman.

Joran van der Sloot is scheduled to arrive Monday afternoon in the Peruvian capital of Lima, Interpol agent Hilda Manosalva told The Associated Press.

Van der Sloot was temporarily extradited to the U.S. to face charges linked to Holloway’s disappearance, a case that has drawn international attention over the course of two decades.

A few days ago, he admitted that he killed Holloway and disposed of her remains. The disclosure came as he pleaded guilty to charges of trying to extort money from Holloway’s mother in return for information about the location of the body.

U.S. authorities do not have jurisdiction to prosecute van der Sloot for the 2005 slaying on a beach in Aruba, where the statute of limitations for murder has expired. But the revelations have given long-sought answers to Holloway’s next-of-kin.

The Dutch citizen was sentenced to 20 years in prison in the U.S. for extortion and wire fraud, but as part of his plea agreement, that sentence will run concurrently with another one in Peru, where he’s serving a 28-year prison sentence for killing Stephany Flores in 2010.

A 2001 treaty between Peru and the U.S. allows a suspect to be temporarily extradited to face trial in the other country.

More:News

Recommend

PACCAR recalls over 220,000 trucks for safety system issue: See affected models

PACCAR is recalling over 220,000 of its 2021-2025 Peterbilt and Kenworth trucks.  The commercial tru

Need a push to save for retirement? This 401(k) gives you up to $250 cash back

The statistics on Americans' lack of retirement readiness can be startling, with almost 1 in 3 older

FDA seems poised to approve a new drug for ALS, but does it work?

The Food and Drug Administration is likely to approve a controversial new drug for ALS by the end of